Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics Li ...

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...

Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of ...

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The data showed there was a five-year overall survival (OS) rate of 16.7% for the ...

Merck announced that sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago. The pharma giant also narrowed its full-year profit outlook ...